Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure

NASuspendedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Primary Ovarian InsufficiencyPoor Ovarian Response
Interventions
OTHER

OvaPrime Treatment

The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.

Trial Locations (1)

M5G 2K4

TRIO, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

OvaScience, Inc.

INDUSTRY